Cesca Therapeutics Shareholders Reporting Group File 13D A Schedule 13D has been filed with the U.S. Securities and Exchange Commission on behalf of a group of shareholders in Cesca Therapeutics, a company formed by the merger earlier this year of leading cell-therapy device-maker ThermoGenesis Corp. and regenerative medicine clinical therapy company TotipotentRX, engaged in the research, development, and commercialization of point-of-care cell-based therapeutics for use in multiple chronic medical illnesses, including critical limb ischemia and acute myocardial infarction.
Posted on: Tue, 28 Oct 2014 14:30:53 +0000
Trending Topics
Recently Viewed Topics
© 2015